中国医药导报
中国医药期刊欢迎您 今天是   2025年4月4日星期五
设为首页 | 加入收藏 
 
        首 页      期刊介绍      下载中心      关于本刊      投稿指南      期刊订阅      在线留言      广告合作      联系我们      返回中国当代医药网
中国医药导报
  麻醉与疼痛 本期目录 | 过刊浏览 | 高级检索 |
盐酸氢吗啡酮联合罗哌卡因臂丛神经阻滞麻醉对上肢骨折术后镇痛效果的影响
陈彦梅      钱铖▲
中国人民解放军联勤保障部队第九〇四医院常州医疗区麻醉科,江苏常州   213000
Effect of Hydromorphone Hydrochloride combined with Ropivacaine brachial plexus block anesthesia on postoperative analgesia of upper limb fractures#br#
CHEN Yanmei   QIAN Cheng▲
Department of Anesthesiology, Changzhou Medical District, 904th Hospital of the Joint Logistic Support Force of the Chinese People’s Liberation Army, Jiangsu Province, Changzhou   213000, China
全文: PDF (568 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 目的 探讨盐酸氢吗啡酮联合罗哌卡因臂丛神经阻滞麻醉对上肢骨折术后的镇痛效果。 方法 选取2018年10月至2020年4月中国人民解放军联勤保障部队第九〇四医院收治的122例桡骨下端骨折患者,依据随机数字表法分为研究组(61例)、对照组(61例)。对照组实施罗哌卡因臂丛神经阻滞麻醉,研究组在对照组的基础上使用盐酸氢吗啡酮。记录两组术后患者自控镇痛(PCA)使用情况及疼痛情况,比较两组血清疼痛介质及药物安全性。 结果 两组术后12、24 h的PCA使用总量高于术后8 h,术后24 h PCA使用总量高于术后12 h,差异有统计学意义(P < 0.05)。研究组术后8、12、24 h PCA使用总量低于对照组,差异有统计学意义(P < 0.05)。两组术后12、24 h的视觉模拟评分法(VAS)评分高于术后4 h,术后24 h的VAS评分高于术后12 h,差异有统计学意义(P < 0.05)。研究组术后4、12、24 h的VAS评分低于对照组,差异有统计学意义(P < 0.05)。术后24 h,两组前列腺素E2(PGE2)、P物质(SP)、多巴胺(DA)高于术前,研究组PGE2、SP、DA低于对照组,差异有统计学意义(P < 0.05)。两组不良反应总发生率比较,差异无统计学意义(P > 0.05)。 结论 盐酸氢吗啡酮联合罗哌卡因臂丛神经阻滞麻醉可减轻上肢骨折患者术后疼痛,减少疼痛介质释放,且安全性良好。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
陈彦梅 钱铖▲
关键词 盐酸氢吗啡酮罗哌卡因臂丛神经阻滞疼痛    
Abstract:Objective To explore the effect of Hydromorphone Hydrochloride combined with Ropivacaine brachial plexus block anesthesia on postoperative analgesia of upper limb fractures. Methods A total of 122 patients with lower radius fractures admitted to 904th Hospital of the Joint Logistic Support Force of the Chinese People’s Liberation Army from October 2018 to April 2020. They were divided into study group (61 cases) and control group (61 cases) according to random number table method. The control group received Ropivacaine brachial plexus block anesthesia, and the study group used Hydromorphone Hydrochloride on the basis of the control group. The use of patient-controlled analgesia (PCA) and pain in two groups were recorded after surgery, serum pain mediators and drug safety of two groups were compared. Results The total PNA usage of both groups at 24 and 12 h after surgery was higher than that at 8 h, the total PCA usage at 12 h in both groups after surgery was higher than that at 12 h, and the differences were statistically significant (P < 0.05). The total PCA usage in study group at 8, 12, and 24 h after surgery was lower than that in control group, and the difference was statistically significant (P < 0.05). Visual analogue scale (VAS) scores of two groups at 24 and 12 h after surgery were higher than those at 4 h, VAS scores of two groups at 24 h after surgery were higher than those at 12 h, and the differences were statistically significant (P < 0.05). VAS of study group at 4, 12, and 24 h after surgery were lower than those of control group, and the differences were statistically significant (P < 0.05). At 24 h after surgery, the levels of prostaglandin E2 (PGE2), substance P (SP) and dopamine (DA) in two groups were higher than those before surgery, PGE2, SP, and DA of study group were lower than those of control group, and the differences were statistically significant (P < 0.05). There was no significant difference in the total incidence of adverse reactions between two groups (P > 0.05). Conclusion Hydromorphone Hydrochloride combined with Ropivacaine brachial plexus block anesthesia can reduce postoperative pain in patients with upper limb fractures, reduce the release of pain mediators, and have good safety.
Key wordsHydromorphone Hydrochloride    Ropivacaine    Brachial plexus block    Pain
    
基金资助:江苏省自然科学基金资助项目(BK20181113)。
通讯作者: ▲通讯作者   
引用本文:   
陈彦梅 钱铖▲. 盐酸氢吗啡酮联合罗哌卡因臂丛神经阻滞麻醉对上肢骨折术后镇痛效果的影响[J]. 中国医药导报, 2022, 19(13): 107-110.
CHEN Yanmei QIAN Cheng▲. Effect of Hydromorphone Hydrochloride combined with Ropivacaine brachial plexus block anesthesia on postoperative analgesia of upper limb fractures#br#. 中国医药导报, 2022, 19(13): 107-110.
链接本文:  
https://www.yiyaodaobao.com.cn/CN/     或     https://www.yiyaodaobao.com.cn/CN/Y2022/V19/I13/107

 

中华人民共和国互联网药品信息服务资格证书(京)-非经营性-2016-0092
京ICP11001767号-2  京公网安备 11010502046598号  期刊出版许可证 广告经营许可证
信息产业部备案管理系统网址 http://beian.miit.gov.cn/state/outPortal/loginPortal.action
投稿热线:010-59626203
本刊地址:北京市朝阳区东四环中路78号楼(大成国际中心B1座)8B02室 邮编:100124
传真:010-59626204 投稿信箱:ddyy@vip.163.com
版权所有:中文传媒集团北京期刊有限公司
技术支持:北京玛格泰克科技发展有限公司